FOXP3 and colorectal carcinoma: In addition, immunohistochemistry results showed that FOXP3 expression in the tumor tissues of CRC patients with neoadjuvant therapy (Folfox therapy) was higher than that without neoadjuvant therapy (Fig. 3j).